Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 6, 2014, Pages 1209-1220

  Bartneck, Matthias ^a   Peters, Franziska Marie ^a   Warzecha, Klaudia Theresa ^a   Bienert, Michaela ^b   van Bloois, Louis ^c   Trautwein, Christian ^a   Lammers, Twan ^a,c,d   Tacke, Frank ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Cell activation; Cell migration; Corticosteroids; Cytokine release; Dexamethasone; Glucocorticoids; Immune cells; Inflammation; Liposomes; Primary human macrophages

Indexed keywords

BODY FLUIDS; CELL CULTURE; DISEASES; DRUG DOSAGE; LIPOSOMES; MACROPHAGES; PHYSIOLOGY;

CELL ACTIVATION; CELL MIGRATION; CORTICOSTEROIDS; CYTOKINES; DEXAMETHASONES; GLUCOCORTICOIDS; HUMAN MACROPHAGES; IMMUNE CELLS; INFLAMMATION;

DRUG PRODUCTS;

DEXAMETHASONE; DIPALMITOYLPHOSPHATIDYLCHOLINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOSOME; PHOSPHATIDYLETHANOLAMINE; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; CYTOKINE;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOTOXICITY; ENCAPSULATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; LIPOSOMAL DELIVERY; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY CELL; ZETA POTENTIAL; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY;

ANTI-INFLAMMATORY AGENTS; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DEXAMETHASONE; HUMANS; LIPOSOMES; MACROPHAGES;

EID: 84905250766     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.02.011     Document Type: Article

References (32)

1. Crielaard B.J., Lammers T., Schiffelers R.M., Storm G. Drug targeting systems for inflammatory disease: one for all, all for one. J Control Release 2012, 161:225-234.
2. van den Hoven J.M., Hofkens W., Wauben M.H., Wagenaar-Hilbers J.P., Beijnen J.H., Nuijen B., et al. Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis. Int J Pharm 2011, 416:471-477.
3. Schweingruber N., Haine A., Tiede K., Karabinskaya A., van den Brandt J., Wust S., et al. Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. J Immunol 2011, 187:4310-4318.
4. Moreau P. Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma. Expert Rev Anticancer Ther 2009, 9:885-890.
5. Luk B.T., Fang R.H., Zhang L. Lipid- and polymer-based nanostructures for cancer theranostics. Theranostics 2012, 2:1117-1126.
6. Moingeon P. Adjuvants for allergy vaccines. Hum Vaccin Immunotherapeutics 2012, 8:1492-1498.
7. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603.
8. Bartneck M., Keul H.A., Singh S., Czaja K., Bornemann J., Bockstaller M., et al. Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry. ACS Nano 2010, 4:3073-3086.
9. Bartneck M., Ritz T., Keul H.A., Wambach M., Bornemann J., Gbureck U., et al. Peptide-functionalized gold nanorods increase liver injury in hepatitis. ACS Nano 2012, 6:8767-8777.
10. Zwadlo G., Voegeli R., Schulze Osthoff K., Sorg C. A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol 1987, 55:295-304.
11. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci 2008, 13:453-461.
12. Nestler U., Winking M., Boker D.K. The tissue level of dexamethasone in human brain tumors is about 1000 times lower than the cytotoxic concentration in cell culture. Neurol Res 2002, 24:479-482.
13. Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985, 812:55-65.
14. Fiske C.H., Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem 1925, 66:375-400.
15. Rouser G., Fkeischer S., Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970, 5:494-496.
16. Metselaar JM. Liposomal Targeting of glucocorticoids: [U+202A]a novel treatment approach for inflammatory disorders. [PhD thesis]. Utrecht: Utrecht University; 2003.
17. Metselaar J.M., Wauben M.H., Wagenaar-Hilbers J.P., Boerman O.C., Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003, 48:2059-2066.
18. Bartneck M., Keul H.A., Wambach M., Bornemann J., Gbureck U., Chatain N., et al. Effects of nanoparticle surface-coupled peptides, functional endgroups, and charge on intracellular distribution and functionality of human primary reticuloendothelial cells. Nanomedicine 2012, 8:1282-1292.
19. Bartneck M., Heffels K.H., Pan Y., Bovi M., Zwadlo-Klarwasser G., Groll J. Inducing healing-like human primary macrophage phenotypes by 3D hydrogel coated nanofibres. Biomaterials 2012, 33:4136-4146.
20. Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000, 18:301-313.
21. Bilzer M., Roggel F., Gerbes A.L. Role of Kupffer cells in host defense and liver disease. Liver Int 2006, 26:1175-1186.
22. Zimmermann H.W., Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 2011, 10:509-536.
23. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
24. van Rooijen N., Sanders A., van den Berg T.K. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 1996, 193:93-99.
25. Ogura Y., Sutterwala F.S., Flavell R.A. The inflammasome: first line of the immune response to cell stress. Cell 2006, 126:659-662.
26. Tacke F., Randolph G.J. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006, 211:609-618.
27. Ingersoll M.A., Platt A.M., Potteaux S., Randolph G.J. Monocyte trafficking in acute and chronic inflammation. Trends Immunol 2011, 32:470-477.
28. Davis J.M., Colangelo J. Small-molecule inhibitors of the interaction between TNF and TNFR. Future Med Chem 2013, 5:69-79.
29. Parameswaran N., Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010, 20:87-103.
30. Vincent F.B., Morand E.F., Murphy K., Mackay F., Mariette X., Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013, 72:165-178.
31. Khokhar O.S., Lewis J.H. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010, 28:508-518.
32. Dinarello C.A., Donath M.Y., Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010, 17:314-321.